Drug Discovery Today

Article	Citations
Demystifying the potential of inhibitors targeting DNA topoisomerases in unicellular protozoan parasites	286
Repurposing of parenterally administered active substances used to treat pain both systemically and locally	242
The potential value of 5-androstenediol in countering acute radiation syndrome	213
Contents page	201
Opportunities and challenges in drug discovery targeting the orphan receptor GPR12	155
Dysbiosis versus diabesity: Pathological signaling and promising therapeutic strategies	154
On-body drug delivery systems: State-of-the-art technologies, clinical application, and future perspectives	141
Computational modeling approaches and regulatory pathways for drug combinations	134
Tubulin targeting agents and their implications in non-cancer disease management	130
Multiple strategies for the treatment of invasive breast carcinoma: A comprehensive prospective	124
Advancing drug repurposing research: Trends, collaborative networks, innovation and knowledge leaders	123
Antibody–drug conjugates: What drives their progress?	122
CIPDB: A biological structure databank for studying cation and π interactions	103
The global status of bioequivalence trials: a comprehensive clinical trial landscape analysis based on the Trialtrove database	103
Gastroretentive drug delivery systems: A holy grail in oral delivery	102
Redox active or thiol reactive? Optimization of rapid screens to identify less evident nuisance compounds	98
The recent progress of deep-learning-based in silico prediction of drug combination	97
From promise to progress: the dynamic landscape of glioblastoma immunotherapy	95
Bridging data and drug development: Machine learning approaches for next-generation ADMET prediction	94
Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy	92
Achieving end-to-end success in the clinic: Pfizer’s learnings on R&D productivity	91
A global bibliometric and visualized analysis of bacteria-mediated cancer therapy	88
Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five	88
Models and approaches to comprehend and address glial inflammation following spinal cord injury	87
General aspects of powder rheology applied to pharmaceutical formulations	86

Targeted drug delivery to the retinal pigment epithelium: Untapped therapeutic potential for retinal diseases	85
Generative AI: driving productivity and scientific breakthroughs in pharmaceutical R&D	83
Exploration of small-molecule inhibitors targeting Hsp110 as novel therapeutics	82
Molecular approaches for the treatment and prevention of Friedreich's ataxia	79
Global landscape and translational trajectories of flavonoid-based wound-healing research	78
Bridging informatics and medicinal inorganic chemistry: Toward a database of metallodrugs and metallodrug candidates	78
Organoids in modelling infectious diseases	77
Targeted protein degradation: current molecular targets, localization, and strategies	75
Regulatory approvals of therapeutic biologics: continuing progress or plateauing out compared with those of small molecules?	74
Translational PK/PD: a retrospective analysis of performance and impact from a drug portfolio	72
Steps toward nebulization in-use studies to understand the stability of new biological entities	72
Gaps between medical biology and AI drug discovery	72
Towards Pharma 4.0 in clinical trials: A future-orientated perspective	66
The emerging role of fatty acid binding protein 7 (FABP7) in cancers	65
Recent advancements in mass spectrometry for higher order structure characterization of protein therapeutics	65
Caught between a ROCK and a hard place: current challenges in structure-based drug design	65
Systematic review and QSPR analysis of chemical penetration through the nail to inform onychomycosis candidate selection	64
Triple-negative breast cancer brain metastasis: An update on druggable targets, current clinical trials, and future treatment options	64
MTHFD2: A significant mitochondrial metabolic enzyme and a novel target for anticancer therapy	63
Recent advances towards overcoming the blood–brain barrier	63
The main aspects of non-clinical studies required for obtaining marketing authorisation for small molecules and biologics/biopharmaceuticals in the European Union and the United States	60
Master protocols and other innovative trial designs in inflammation and immunology to expedite clinical drug development	60
ImmunoPET imaging of hematological malignancies: From preclinical promise to clinical reality	60
Pathogenic TDP-43 in amyotrophic lateral sclerosis	59
MRI assessment of cerebral perfusion in clinical trials	59
Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein	59
Lipid- and polymer-based formulations containing TNF-α inhibitors for the treatment of inflammatory bowel diseases	59
Investigating miRNA subfamilies: Can they assist in the early diagnosis of acute myocardial infarction?	58
Advancing pharmacogenetics research in Africa: the “Project Africa GRADIENT” initiative	58
Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance	57
Randomized controlled trials do not always fit the purpose: A science-based response to Venetis and Mol’s editorial on biosimilars of follitropin alfa	57
Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases	57
Embryonic and larval zebrafish models for the discovery of new bioactive compounds against tuberculosis	57
Unlocking therapeutic frontiers: harnessing artificial intelligence in drug discovery for neurodegenerative diseases	57
Metabolic reprogramming: Unveiling the therapeutic potential of targeted therapies against kidney disease	55
Lactose in tablets: Functionality, critical material attributes, applications, modifications and co-processed excipients	55
PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?	54
Medicinal chemistry aspects of uracil containing dUTPase inhibitors targeting colorectal cancer	54
Oral delivery of nucleic acid therapeutics: Challenges, strategies, and opportunities	54
Therapeutic strategies targeting ocular vasculopathies: Current advances and emerging challenges	54
Genetic–epigenetic targets for PCOS-associated diabesity	53
A review on the recent advances of interaction studies of anticancer metal-based drugs with therapeutic targets, DNA and RNAs	53
50 shades of AI in regulatory science	52
Regulatory readiness to facilitate the appropriate use of innovation in clinical trials: The case of decentralized clinical trial approaches	52
Sustainability by design for recombinant protein therapeutics	52
Elevating life science R&D success with AI: a framework	51
An overview of progress in human metapneumovirus (hMPV) research: Structure, function, and therapeutic opportunities	50
PolyBodies for the Treatment of Respiratory Syncytial Virus Infection	50
In silico resources help combat cancer drug resistance mediated by target mutations	50
Global or local: The future of biotech	49

Opioid epidemic and the urge to discover new treatment options	49
Hippo signaling in acute kidney injury to chronic kidney disease transition: Current understandings and future targets	48
Contents page	48
IRE1α-mediated UPR activation in gastrointestinal cancers: Adaptive mechanisms and therapeutic potential	48
Review of the impact of the FDA’s Fast Track Designation on biotechnology companies’ share prices	48
Illuminating function of the understudied druggable kinome	47
Recent insights into viral infections as a trigger and accelerator in alzheimer's disease	47
Indole therapeutics: Latest FDA updates, ongoing trials, and future directions	47
Exosomal heterogeneity and functional zonation in cancer drug resistance	47
Back on the scene: Advances and challenges in CD3-related drugs in tumor therapy	47
The role of gut microbial β-glucuronidase in drug disposition and development	46
Disruptions in bioactivity driven by dose: a challenge for drug discovery	46
Potential nanocarrier-mediated miRNA-based therapy approaches for multiple sclerosis	46
Impact of HDAC inhibitors on macrophage polarization to enhance innate immunity against infections	46
Development of LRRK2 inhibitors through computational strategies: a promising avenue for Parkinson’s disease	45
Recent advances in dual-drug co-amorphous systems	44
Renal cell carcinoma therapy: Current and new drug candidates	44
Drugs from drugs: New chemical insights into a mature concept	44
Structural biology of plant-derived antibacterials: opportunities for rational lead optimization	43
Advancements and challenges in using AI for biomarker detection in early Alzheimer’s disease	43
Open innovation: A paradigm shift in pharma R&D?	43
CPPsite3: An updated large repository of experimentally validated cell-penetrating peptides	43
Self-amplifying mRNA vaccines: Mode of action, design, development and optimization	42
Overview of new indications for novel drugs approved in China between 2018 and 2024	42
Cubosome-based cosmeceuticals: A breakthrough in skincare	42
Recent advances in multitarget-directed ligands via in silico drug discovery	42
Vaginal drug delivery system: A promising route of drug administration for local and systemic diseases	41
Decentralised, patient-centric, site-less, virtual, and digital clinical trials? From confusion to consensus	41
UCP1 activation: Hottest target in the thermogenesis pathway to treat obesity using molecules of synthetic and natural origin	41
2023 in review: FDA approvals of new medicines	40
Corrigendum to “Therapeutic potential of fucosyltransferases in cancer and recent development of targeted inhibitors” [Drug Discov. Today 28(1) (2023) 103394]	40
Transforming patient engagement in clinical trials: Moving from a transactional relationship to human-centered care	40
Corrigendum to “Role of transient receptor potential channels in the regulation of vascular tone” [Drug Discov. Today 29(7) (2024) 104051]	40
Pharmaceutical strategies for the treatment of bacterial biofilms in chronic wounds	40
The Unitary Patent and UPC – Implications for the pharmaceutical sector	40
Science of, and insights into, thermodynamic principles for dermal formulations	40
Does pharma R&D need a strategic reset? Adapting to a changing US landscape	40
Metabophore-mediated retro-metabolic (‘MeMeReMe’) approach in drug design	40
Strategizing the human microbiome for small molecules: Approaches and perspectives	40
Artificially engineered bacteria to treat gastrointestinal disease and cancer	39
Compound–protein interaction prediction by deep learning: Databases, descriptors and models	39
Operational and path dependencies impede the feasibility of hospital-based production of individually engineered drugs	38
Artificial intelligence methods in kinase target profiling: Advances and challenges	38
Advances in lipid-based nanoformulations for inhaled antibiotic therapy in respiratory infections	38
dbDNA™: An advanced platform for genetic medicines	38
Real-world data in drug development strategies for orphan drugs: Tafasitamab in B-cell lymphoma, a case study for an approval based on a single-arm combination trial	38
Neurotrophin peptidomimetics for the treatment of neurodegenerative diseases	38
Small molecules targeting canonical transient receptor potential channels: an update	38
A new era for schizophrenia drug development – Lessons for the future	38
Therapeutic potential of targeting IL-17 and its receptor signaling in neuroinflammation	37
Geometric deep learning methods and applications in 3D structure-based drug design	37
Recent advances in flavonoid-based nanocarriers as an emerging drug delivery approach for cancer chemotherapy	37
Therapeutic targeting of the complement system in ocular disease	37
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236	37
Innovation testbeds as enabling ecosystems driving nanopharmaceuticals to market	37
Nanoformulations of chemotherapeutic activators of the cGAS–STING pathway in tumor chemoimmunotherapy	37
PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery	37
Molecular medicinal insights into scaffold hopping-based drug discovery success	36
The expanding repertoire of covalent warheads for drug discovery	36
Insight into the pivotal role of signaling pathways in psoriasis pathogenesis, potential therapeutic molecules and drug delivery approaches	36
The importance of a go-to-market strategy in the commercialisation of cellular immunotherapies	35
Targeting hepatitis B virus cccDNA levels: Recent progress in seeking small molecule drug candidates	35
Harnessing G-quadruplex ligands for lung cancer treatment: A comprehensive overview	35
Oncological drug discovery: AI meets structure-based computational research	35
Death ligand receptor (DLR) signaling: Its non-apoptotic functions in cancer and the consequences of DLR-directed therapies	35
Approaches to advance drug discovery for neglected tropical diseases	35
Regulatory oversight on the use of experimental therapies during a pandemic: The case of early access to convalescent plasma therapy in three LMICs	34
Druggable genome special issue: An introduction	34
Targeting autophagy in colorectal cancer: An update on pharmacological small-molecule compounds	34
Corrigendum to “Critical path activities in clinical trial setup & conduct – How to avoid bottlenecks and accelerate clinical trials” [Drug Discov. Today 28(10) (2023) 103733]	34
Advancing ocular gene therapy: a machine learning approach to enhance delivery, uptake and gene expression	34
Harnessing personalized tailored medicines to digital-based data-enriched edible pharmaceuticals	34
Peptide-derived ligands for the discovery of safer opioid analgesics	34
Corrigendum to “Pharmacological modulation of autophagy for epilepsy therapy: Opportunities and obstacles” [Drug Discov. Today 28(6) (2023) 103600]	34
Contents page	34
A retrospective regulatory analysis of FDA recalls carried out by pharmaceutical companies from 2012 to 2023	33
Piezo1 as a therapeutic target in kidney disease: emerging mechanistic insights and translational potential	33
Advances in antibody-based strategies for targeting cancer-associated glycopeptide antigens	33
How health technology assessment can help to address challenges in drug repurposing: a conceptual framework	33
Expanding therapeutic potential of Bdellovibrio bacteriovorus against multidrug-resistant pathogens	33

A pipeline analysis of advanced therapy medicinal products	32
Blocking platelet glycoprotein VI (GPVI) as a promising antithrombotic treatment	32
IdopNetwork as a genomic predictor of drug response	32
‘Home inspections’ for life sciences companies going public before clinical proof-of-concept	32
Nanomedicine approaches to reduce cytokine storms in severe infections	32
Small molecule inhibitors of the co-receptor neuropilin-1	32
Early career researchers’ experiences in drug discovery in Africa	32
Deadly interactions: Synergistic manipulations of concurrent pathogen infections potentially enabling future pandemics	32
Effectiveness of histamine receptor antagonists in the treatment of histamine-driven clinical symptoms: do we have a histamine or, better, an anti-histamine problem?	31
ADAM10: Function insights, disease implications, and promise of therapeutic targeting	31
Recent discoveries of the role of histone modifications and related inhibitors in pathological cardiac hypertrophy	31
Nanophotonic waveguide-based sensing of circulating cell-free mitochondrial DNA: implications for personalized medicine	31
Drugging the entire human proteome: Are we there yet?	31
Competition of regulatory ecosystems in approving medicines: policy implications in the case of Europe	31
Lysine lactylation: Regulatory mechanisms, role in health and disease, and its therapeutic potential	31
Publisher’s Note	31
Regulating NETosis: An emerging facet of statin pleiotropy	31
Opportunities and challenges of physiologically based pharmacokinetic modeling in drug delivery	30
Chiral-engineered supraparticles: Emerging tools for drug delivery	30
Evaluating the performance of drug-repurposing technologies	30
Using computers to ESKAPE the antibiotic resistance crisis	30
Translating precision medicine for autism spectrum disorder: A pressing need	30
Machine learning and natural language processing in clinical trial eligibility criteria parsing: a scoping review	30
Therapies for Inherited Retinal Dystrophies: What is Enough?	29
TDP-43 protein interactome informs about perturbed canonical pathways and may help develop personalized medicine approaches for patients with TDP-43 pathology	29
Recent progress in covalent organic frameworks for cancer therapy	29
Evaluation of the implementation effectiveness of accelerated drug marketing registration procedures in China: lessons from the 2016–2024 regulatory review	29
Orphan GPR52 as an emerging neurotherapeutic target	29
Targeting SIRT1-regulated autophagic cell death as a novel therapeutic avenue for cancer prevention	29
Surface-enhanced Raman scattering biosensors for detection of oncomiRs in breast cancer	29
Exosome-mediated PROTAC delivery for treatment of RNA viral infections and zoonosis	29
Antimicrobial and anti-biofilm activities of bio-inspired nanomaterials for wound healing applications	29
COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease	29
Biopharmaceutical R&D outsourcing: Short-term gain for long-term pain?	28
A personalized pharmaco-epistatic network model of precision medicine	28
Prospects of halofuginone as an antiprotozoal drug scaffold	28
Benefits of hybrid QM/MM over traditional classical mechanics in pharmaceutical systems	28
Integrating heterogeneous data to facilitate COVID-19 drug repurposing	28
Patents, trade secrets and pricing	28
A review of the efficacy of prostate cancer therapies against castration-resistant prostate cancer	28
Optical tweezers for drug discovery	28
Recent advances in the molecular design and applications of viral RNA-targeting antiviral modalities	28
Generic dry powder inhalers bioequivalence: Batch–to-batch variability insights	28
Sustaining pharmaceutical innovation after the Inflation Reduction Act: trends in R&D spending, equity investment, and business development	28
Electrospun proliposomes and the quest to overcome liposome instability	28
Methionine biosynthesis as a key metabolic pathway for antimicrobial drug discovery in Streptococcus mutans	27
Therapeutic potential of fucosyltransferases in cancer and recent development of targeted inhibitors	27
Trends, challenges, and success factors in pharmaceutical portfolio management: Cognitive biases in decision-making and their mitigating measures	27
Peptide modulators of cell migration: Overview, applications and future development	27
Which cryptic sites are feasible drug targets?	27
Novel and investigational therapies for wet and dry age-related macular degeneration	27
ATP-binding cassette efflux transporters and MDR in cancer	26
Concepts and applications of chemical fingerprint for hit and lead screening	26
Recent trends in targeted delivery of smart nanocarrier-based microbial enzymes for therapeutic applications	26
Non-oncology orphan drug development: Productivity and probability of success	26
Beyond CL and VSS: A comprehensive approach to human pharmacokinetic predictions	26
Active pharmaceutical ingredients (APIs) in ionic liquids: An effective approach for API physiochemical parameter optimization	26
Applications of density functional theory in COVID-19 drug modeling	26
Comparative analysis of FDA approvals by top 20 pharma companies (2014–2023)	26
Rational discovery of molecular glue degraders based on block chemistry	26
Clinical significance and potential role of trimethylamine N-oxide in neurological and neuropsychiatric disorders	26
Can preclinical drug development help to predict adverse events in clinical trials?	26
Shining light on liquid–liquid phase separation in chronic liver disease	26
Contents page	25
Electron diffraction: Accelerating drug development	25
Commercialization of cell and gene therapy in Canada: Current landscape, challenges and opportunities	25
Positron emission tomographic imaging in drug discovery	25
How can MSI enhance our understanding of ASO distribution?	25
Contents page	25
On the pivotal role of drug discovery in sustainable EU pharma reform	25
Aceclofenac and methotrexate combination therapy could influence Th1/Th17 axis to modulate rheumatoid-arthritis-induced inflammation	25
Rapid progress in neuroimaging technologies fuels central nervous system translational medicine	25
Informatic challenges and advances in illuminating the druggable proteome	25
Contents page	25
Metallocompounds as anticancer agents against osteosarcoma	25
Machine learning in targeted protein degradation drug design: a technical review of PROTACs and molecular glues	25
Nanosponges: An overlooked promising strategy to combat SARS-CoV-2	25
Epigenetic roles of lysine-specific demethylase 1 (LSD1) in cancer metabolism	24
Covalent ligand efficiency	24
Circadian disruption in hepatocellular carcinoma: Current findings and future directions of molecular mechanisms	24
Statins and angiogenesis in non-cardiovascular diseases	24
SET7, a lysine-specific methyl transferase: An intriguing epigenetic target to combat diabetic nephropathy	24
Grasping cryptic binding sites to neutralize drug resistance in the field of anticancer	24
How missing value imputation is confounded with batch effects and what you can do about it	24
New approaches for challenging therapeutic targets	24
The role of venom proteomics and single-domain antibodies for antivenoms: Progress in snake envenoming treatment	24
Dual-action potential of cationic cryptides against infections and cancers	24
An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020	23
Illuminating the druggable genome: Pathways to progress	23
Brain-derived neurotrophic factor (BDNF) in perinatal depression: Side show or pivotal factor?	23
Pivotal role of nitrogen heterocycles in Alzheimer’s disease drug discovery	23
Advantages, progress, and future trends in oral medicated jellies/gels: Focus on adherence aspects	23
Treating liver cancer through arginine depletion	23
Carbon dots in oncology: multifunctional nanoplatforms for diagnosis, targeted therapy, and drug discovery	23
Drugs targeting peroxisome proliferator-activated receptors	22